Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-3450074 (PF-74)是 HIV-1 衣壳蛋白的特异性抑制剂,可广谱抑制 HIV 分离株。它在 HIV-1 感染的早期阶段起作用,通过与 CPSF6 和 NUP153 的结合直接竞争来抑制病毒复制,并阻断病毒生命周期的脱膜,组装和逆转录步骤。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
2 mg | ¥ 258 | 现货 | ||
5 mg | ¥ 398 | 现货 | ||
10 mg | ¥ 747 | 现货 | ||
25 mg | ¥ 1,230 | 现货 | ||
50 mg | ¥ 1,980 | 现货 | ||
100 mg | ¥ 3,730 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 455 | 现货 |
产品描述 | PF-3450074 (PF-74) acts at an early stage of HIV-1 infection inhibits viral replication by directly competing with the binding of CPSF6 (nuclear host factors cleavage and polyadenylation specific factor 6) and NUP153 (nucleoporin 153), and blocks the uncoating, assembly, and the reverse transcription steps of the viral life cycle. PF-3450074 is a specifical inhibitor of HIV-1 capsid protein (CA) and shows a broad-spectrum inhibition of HIV isolates with submicromolar potency (EC50=8-640 nM). |
靶点活性 | HIV-1:0.72 μM(NL4.3 strain) |
体外活性 | PF-3450074 displays a good potency in primary human peripheral blood mononuclear cells (PBMCs), inhibits HIV-193RW025, HIV-1JR-CSF and HIV-193MW965 with IC50 values of 1.5 ± 0.9 μM; 0.6 ± 0.20 μM; and 0.6 ± 0.10 μM, respectively. PF-3450074 shows anti-viral activities against HIV wild type NL4-3 and HIV T107N mutant (EC50: 0.72 μM and 4.5μM, respectively). PF-3450074 (10 μM; 8 hours) causes a marked reduction in late products of reverse transcription in HeLa-P4 cells with DNase I-treated stocks of Env-defective HIV-1 (R9.Env-). This compound shows Median IC50?and CC50?values of 0.9 ± 0.5 μM and 90.5 ± 5.9 μM, respectively. The KD?for the interaction between?PF-74?and the CA hexamer, derived in the same manner as for NUP153, is determined to be 176 ± 78 nM [1][2]. |
细胞实验 | HeLa-P4 cells were inoculated with PF74 (10 μM). After 8 h of culture, the cells were harvested and DNA isolated with a DNeasy Blood & Tissue kit (Qiagen). HIV-1 DNA in the samples was quantified by real-time PCR using primers specific which shows that PF74 inhibited HIV-1 reverse transcription in target cells. |
别名 | PF-74 |
分子量 | 425.52 |
分子式 | C27H27N3O2 |
CAS No. | 1352879-65-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 249 mg/mL (585.16 mM), Sonification is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.3501 mL | 11.7503 mL | 23.5007 mL | 58.7516 mL |
5 mM | 0.47 mL | 2.3501 mL | 4.7001 mL | 11.7503 mL | |
10 mM | 0.235 mL | 1.175 mL | 2.3501 mL | 5.8752 mL | |
20 mM | 0.1175 mL | 0.5875 mL | 1.175 mL | 2.9376 mL | |
50 mM | 0.047 mL | 0.235 mL | 0.47 mL | 1.175 mL | |
100 mM | 0.0235 mL | 0.1175 mL | 0.235 mL | 0.5875 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PF-3450074 1352879-65-2 Microbiology/Virology Proteases/Proteasome HIV Protease capsid protein inhibit PF 3450074 PF-74 PBMC PF74 Human immunodeficiency virus Inhibitor PF3450074 PF 74 HIV inhibitor